The Humanoid M.AX Alliance is a public-private platform uniting AI model developers, robot makers, component suppliers, end-user companies and universities. It builds a full-cycle humanoid robot ecosystem and drives open innovation with 200+ members to boost future manufacturing competitiveness.
HiStranger.Inc
HiStranger is a content-focused deep-tech company pioneering the Emotion AI market through biosignal-based multimodal analysis solution [Insight Flow]. Combining advanced R&D with our proprietary platforms, we deliver intelligent data-driven solutions that drive market-leading content innovation and empower creators worldwide.
FutureDrive Inc.
FutureDrive pioneers unmanned mobile EV charging by combining autonomous driving, tele-operation, and AI. Its flagship T-CHARGE is the world’s first trailer-type tele-operated charging platform, enabling flexible on-demand charging in areas with limited infrastructure, guided by the vision “Scalable Autonomy for Every Mobility”
EXIONLabs Inc
EXIONLabs is a digital healthcare startup that enhances the safety and efficiency of pharmacy dispensing with robotics and AI. Backed by the founder’s global experience, we develop solutions that address persistent challenges in real pharmacy settings and move toward a future in which healthcare is safer and more reliable for everyone.
DDna Pet Co., Ltd.
MungAI is an AI pet-tech startup transforming pet monitoring into proactive safety prevention. Our technology detects abnormal behavior in real time and enables early intervention across homes and pet facilities worldwide.
CTCELLS
CTCELLS is an innovative cancer diagnostics and drug development company founded on the belief that effective cancer care requires solutions tailored to each individual. Powered by Circulating Tumor Cell (CTC) liquid biopsy, CTCELLS enables automated isolation of diverse CTC subtypes to better capture the full biological heterogeneity of cancer. To translate these insights into actionable research and clinical value, CTCELLS integrates its proprietary Continuous Centrifugal Microfluidics (CCM) technology for robust, automated CTC processing, lossless cell staining enabled by hydrogel-based HypICC to preserve cellular information for downstream analysis, and single-cell picking to support precise molecular profiling and functional characterization. By connecting cancer-specific cellular characteristics with the most suitable therapies, CTCELLS is committed to improving patient outcomes and accelerating the development of next-generation treatments, bringing new hope to patients facing difficult-to-treat cancers. | CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient’s unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products.